Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 1045Lung Neoplasms 803Small Cell Lung Carcinoma 193Breast Neoplasms 158Colorectal Neoplasms 157Neoplasms 128Melanoma 116Ovarian Neoplasms 111Pancreatic Neoplasms 107Stomach Neoplasms 95Neoplasm Metastasis 89Esophageal Neoplasms 77Squamous Cell Carcinoma of Head and Neck 75Prostatic Neoplasms 66Uterine Cervical Neoplasms 65Head and Neck Neoplasms 65Endometrial Neoplasms 61Triple Negative Breast Neoplasms 59Colonic Neoplasms 58Carcinoma, Renal Cell 58Mesothelioma, Malignant 48Adenocarcinoma of Lung 48Urinary Bladder Neoplasms 47Carcinoma, Hepatocellular 46Mesothelioma 42Sarcoma 40Brain Neoplasms 40Liver Neoplasms 38Disease 34NSCLC 33

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Non-Small Cell Lung Cancer With EGFR Mutation × Thoracic × Clear all
NCT06668103 2024-12-12

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Abbisko Therapeutics Co, Ltd

Phase 2 Recruiting
54 enrolled
Thoracic

Non-Small Cell Lung Cancer With EGFR Mutation

NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Suzhou Genhouse Bio Co., Ltd.

Phase 1/2 Recruiting
94 enrolled
Thoracic

Non-Small Cell Lung Cancer With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡